Bymark Leiser News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting.More than half of patients who received zanidatamb (Jazz Pharmaceuticals/Zymeworks) monotherapy survived at least a year and median OS exceeded 15 months.

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.The analysis — which included patients with hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer that progressed after endocrine therapy — also showed considerably

CHICAGO — Comprehensive prescription drug monitoring program mandates appeared associated with a moderate reduction in the number of opioid analgesics dispensed to people dying of cancer, according to study results.Reductions were two to three times higher among non-Hispanic Black and Asian/Pacific Islander decedents than non-Hispanic white decedents, findings presented at ASCO Annual

CHICAGO — ASCO and American Cancer Society will collaborate to make it easier for patients and their caregivers to find credible cancer information online.The effort is intended to establish one of the largest, most comprehensive online sources of authoritative cancer information.

CHICAGO — High-deductible health plans appeared associated with shorter survival among cancer survivors, according to results of a nationwide population-based analysis presented at ASCO Annual Meeting.The findings suggest high-deductible health plans may create a financial disincentive for cancer survivors that prevents them from seeking necessary medical care, according to Justin Barnes,